ArticleDiseases (Basel, Switzerland)2024

Cost-Utility Analysis of PCSK9 Inhibitors and Quality of Life: A Two-Year Multicenter Non-Randomized Study.

José Seijas-Amigo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.